<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">15090872</PMID>
      <DateCompleted>
        <Year>2004</Year>
        <Month>07</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1350-7540</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>17</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2004</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current opinion in neurology</Title>
          <ISOAbbreviation>Curr Opin Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ménière's disease.</ArticleTitle>
        <Pagination>
          <StartPage>9</StartPage>
          <EndPage>16</EndPage>
          <MedlinePgn>9-16</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Ménière's disease is characterized by spontaneous attacks of vertigo, fluctuating sensorineural hearing loss, aural fullness, and tinnitus. The pathologic process involves distortion of the membranous labyrinth with the formation of endolymphatic hydrops. This review describes the pathogenesis and etiology as well as the diagnosis and treatment of Ménière's disease.</AbstractText>
          <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Initial management of Ménière's disease can involve a low-salt diet and a diuretic. Treatment with intratympanic injection of gentamicin can be beneficial when vertigo persists despite optimal medical management. Recent studies have shown that gentamicin reduces vestibular function in the treated ear, although complete ablation of this vestibular function is not typically required in order to achieve control of vertigo.</AbstractText>
          <AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Vertigo is often the most debilitating symptom associated with Ménière's disease. Many treatment options exist for the management of vertigo. Intratympanic injection of gentamicin (low dose) can be used in patients for whom vertigo has not been controlled by medical measures. Ongoing research is providing a greater understanding of the effects of gentamicin on vestibular function and of the mechanisms through which gentamicin leads to control of vertigo.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Minor</LastName>
            <ForeName>Lloyd B</ForeName>
            <Initials>LB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-0910, USA. lminor@jhmi.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schessel</LastName>
            <ForeName>David A</ForeName>
            <Initials>DA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carey</LastName>
            <ForeName>John P</ForeName>
            <Initials>JP</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Curr Opin Neurol</MedlineTA>
        <NlmUniqueID>9319162</NlmUniqueID>
        <ISSNLinking>1350-7540</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004232">Diuretics</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005839">Gentamicins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004039" MajorTopicYN="N">Diet, Sodium-Restricted</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004232" MajorTopicYN="N">Diuretics</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004432" MajorTopicYN="N">Ear, Middle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004584" MajorTopicYN="N">Electronystagmography</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018159" MajorTopicYN="N">Endolymphatic Hydrops</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005839" MajorTopicYN="N">Gentamicins</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008575" MajorTopicYN="N">Meniere Disease</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014724" MajorTopicYN="N">Vestibular Function Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014725" MajorTopicYN="N">Vestibular Nerve</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>83</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2004</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2004</Year>
          <Month>7</Month>
          <Day>20</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2004</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15090872</ArticleId>
        <ArticleId IdType="doi">10.1097/00019052-200402000-00004</ArticleId>
        <ArticleId IdType="pii">00019052-200402000-00004</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
